NLS PHARMA
NLS Pharma is a clinical-stage drug development company focusing on neurobehavioral and neurocognitive disorders and their pharmacognosia. Its patient-centered approach increases the rate for success and our successful collaboration with experts across industry, academia allows for a target specific and customized approach.
NLS PHARMA
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Stans, Nidwalden, Switzerland
Country:
Switzerland
Website Url:
http://www.nlspharma.com
Total Employee:
11+
Status:
Active
Contact:
+41 41 618 80 00
Total Funding:
6.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Apache Global Site Tag ReCAPTCHA
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Yorkville Advisors
Yorkville Advisors investment in Post-IPO Equity - NLS Pharma
Official Site Inspections
http://www.nlspharma.com
- Host name: sl166.web.hostpoint.ch
- IP address: 217.26.53.155
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "NLS Pharma"
Corporate Governance | NLS Pharmaceutics
Name Position; Independent Director (as defined under Nasdaq Stock Market rules) Member of the Audit Committee; Member of the Compensation, Nomination and Governance CommitteeSee details»
NLS Pharmaceutics AG – Swiss Biotech
NLS Pharmaceutics is a NASDAQ listed Swiss-based company engaged in discovery and development of drug therapies for rare and complex central nervous systems disorders. Lead product candidate, Quilience® is under …See details»
History | NLS Pharmaceutics - monsolfoundation.ch
NLS was formed in June 2015 in Stans, Switzerland, and is a Swiss limited company. In 2016, we acquired several patents from Assistance Publique – Hopitaux de Paris, or AP-HP in France, …See details»
NLS Pharmaceutics AG (NLSP) Company Profile & Facts - Yahoo …
See the company profile for NLS Pharmaceutics AG (NLSP) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
NLS Pharmaceutics AG - LinkedIn
Nlspharma.com 52 7 Comments Like Comment Share NLS Pharmaceutics AG 1,329 followers 5mo Report this post NLS Pharmaceutics has been granted an extension by the Nasdaq …See details»
NLS Pharma - Crunchbase Company Profile & Funding
NLS Pharma is a clinical-stage drug development company focusing on neurobehavioral and neurocognitive disorders and their pharmacognosia. Its patient-centered approach increases the rate for success and our successful …See details»
NLS Pharmaceuticals - Overview, News & Similar companies
Aug 19, 2024 NLS Pharmaceuticals has announced that Keith Dewedoff has joined the organization as Interim Chief Financial Officer. Previously, Dewedoff served as Chief Financial …See details»
NLS Pharmaceutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 NLS Pharmaceutics is a biopharmaceutical company engaged in drug discovery for central nervous system disorders. It is focused on the development of therapeutics for …See details»
NLS Pharmaceutics CEO Issues Letter to Shareholders
Dec 11, 2024 Investor Relations [email protected] www.nlspharma.com. SOURCE: NLS Pharmaceutics AG. View the original press release on …See details»
NLS Pharmaceuticals to Reschedule Company Update on Strategic …
Oct 19, 2023 ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...See details»
NLS Pharmaceutics Announces Company Update on Strategic
Oct 12, 2023 For more information, please visit www.nlspharma.com. For additional information: Marianne Lambertson (investors & media) NLS Pharmaceutics Ltd. +1 239.682.8500 ml@nls …See details»
NLS Pharmaceutics Announces Company Update on Strategic …
Oct 12, 2023 Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3,NLS to Webcast its Event Friday, October 20 at 11:00am …See details»
Financial Information | NLS Pharmaceutics - monsolfoundation.ch
This website uses cookies for analysis. You can find exact details in our privacy policy.See details»
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger …
Nov 5, 2024 ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL /November 5th, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and …See details»
NLS Pharmaceutics CEO Issues Letter to Shareholders
Dec 11, 2024 NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and …See details»
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the …
Was sold at Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 8, 2025 — NLS …See details»
NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo …
Dec 29, 2023 Continuing to build an organization dedicated to rare and complex CNS disorders. Solidifying the opportunity for lead product Mazindol ER's success through a rigorous. Phase 3 …See details»
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq …
Oct 28, 2024 www.nlspharma.com. This website uses cookies for analysis. You can find exact details in our privacy policy. No thank you Ok. Partnerships. Contact NLS Pharmaceutics AG …See details»
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F …
Dec 30, 2024 NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative …See details»
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial …
1 day ago NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its …See details»